Comments
Drug firm Cipla Ltd has made an additional investment of $3 million in the US-based Chase Pharmaceuticals engaged in developing novel approaches to improve treatments for Alzheimer’s disease.
The company in May 2014 had invested $1.5 million to acquire 14.6 per cent stake in Chase Pharmaceuticals.
“Cipla (EU) Ltd, UK, a wholly-owned subsidiary of the company...made an additional investment of $3 million in Chase Pharmaceuticals towards full settlement of its obligation under the agreement arrangement for investment in Chase,” Cipla said in a BSE filing.
Consequently, Cipla UK’s total investment in Chase would aggregate to approximately $5.12 million for a 16.7 per cent stake on a fully diluted basis.
Under the agreement in May, Cipla had said it will make an additional $4.5 million investment in Chase upon achievement of certain milestones in this direction.
The investment done through Cipla (EU) Ltd, UK, was part of a $21 million syndicate to finance Phase 2a and Phase 2b clinical trials for Chase’s lead drug CPC 201 for treating the disease.
Other investors in the syndicate were Edmond de Rothschild Investment Partners and New Rhein Healthcare LLC.
The original venture funding for Chase was provided by the Brain Trust Accelerator Fund in 2010.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.